Genetic diversity and antifungal susceptibilities of environmental Cryptococcus neoformans and Cryptococcus gattii species complexes.
Cryptococcus gattii
Cryptococcus neoformans
Antifungal combination
Antifungal susceptibility
Environmental isolates
Genotyping
Minimum inhibitory concentration
Journal
IMA fungus
ISSN: 2210-6340
Titre abrégé: IMA Fungus
Pays: England
ID NLM: 101557546
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
11
04
2023
accepted:
05
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
epublish
Résumé
Cryptococcosis is an opportunistic systemic mycosis caused by Cryptococcus neoformans and C. gattii species complexes and is of increasing global importance. Maintaining continued surveillance of the antifungal susceptibility of environmental C. neoformans and C. gattii isolates is desirable for better managing cryptococcosis by identifying resistant isolates and revealing the emergence of intrinsically resistant species. Relevant research data from Egypt are scarce. Thus, this study aimed to report the genetic diversity of C. neoformans and C. gattii species complexes originating from different environmental sources in Egypt, antifungal susceptibility profiles, antifungal combinations, and correlations of susceptibility with genotypes. A total of 400 environmental samples were collected, 220 from birds and 180 from trees. Cryptococcus spp. were found in 58 (14.5%) of the samples, 44 (75.9%) of the isolates were recovered from birds and 14 (24.1%) from trees. These isolates were genotyped using M13 polymerase chain reaction-fingerprinting and URA5 gene restriction fragment length polymorphism analysis. Of the 31 C. neoformans isolates, 24 (77.4%), 6 (19.4%) and one (4.4%) belonged to VNI, VNII, and VNIII genotypes, respectively. The 27 C. gattii isolates belonged to VGI (70.4%), VGII (18.5%), and VGIII (11.1%) genotypes. Non-wild type C. neoformans and C. gattii isolates that may have acquired resistance to azoles, amphotericin B (AMB), and terbinafine (TRB) were observed. C. gattii VGIII was less susceptible to fluconazole (FCZ) and itraconazole (ITZ) than VGI and VGII. C. neoformans isolates showed higher minimum inhibitory concentrations (MICs) to FCZ, ITZ, and voriconazole (VRZ) than those of C. gattii VGI and VGII. Significant (P < 0.001) correlations were found between the MICs of VRZ and ITZ (r = 0.64) in both C. neoformans and C. gattii isolates, FCZ and TRB in C. neoformans isolates, and FCZ and TRB (r = 0.52) in C. gattii isolates.There is no significant differences in the MICs of TRB in combination with FCZ (P = 0.064) or in combination with AMB (P = 0.543) and that of TRB alone against C. gattii genotypes. By calculating the fractional inhibitory concentration (FIC) index, the combination of FCZ + AMB was synergistic against all tested genotypes. These findings expand our knowledge of ecological niches, genetic diversity, and resistance traits of C. neoformans and C. gattii genotypes in Egypt. Further investigations into how they are related to clinical isolates in the region are warranted.
Identifiants
pubmed: 39060926
doi: 10.1186/s43008-024-00153-w
pii: 10.1186/s43008-024-00153-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Informations de copyright
© 2024. The Author(s).
Références
Abulreesh HH, Organji SR, Elbanna K, Osman GEH, Almalki MHK, Abdel-Mallek AY (2015) First report of environmental isolation of Cryptococcus neoformans and other fungi from pigeon droppings in Makkah, Saudi Arabia and in vitro susceptibility testing. Asian Pacific J Trop Dis 5:622–626
doi: 10.1016/S2222-1808(15)60901-X
Alves GSB, Freire AKL, Bentes AdS, Pinheiro JFdS, de Souza JVB, Wanke B, Matsuura T, Jackisch-Matsuura AB (2016) Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas. Brazil Mycoses 59:509–515
pubmed: 27005969
doi: 10.1111/myc.12499
Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML (2013) Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med Mycol 51:635–640
pubmed: 23343452
doi: 10.3109/13693786.2012.761737
Andrade-Silva LE, Vilas-Boas A, Ferreira-Paim K, Andrade-Silva J, Santos DdA, Ferreira TB, Borges AS, Mora DJ, Melhem MdSC, Silva-Vergara ML (2023) Genotyping analysis of Cryptococcus deuterogattii and correlation with virulence factors and antifungal susceptibility by the clinical and laboratory standards institute and the European committee on antifungal susceptibility testing methods. J Fungi 9:889
doi: 10.3390/jof9090889
Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM (2009) Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy. Rev Iberoam Micol 26:194–197
pubmed: 19635445
doi: 10.1016/j.riam.2009.02.001
Argenta JS, Santurio JM, Alves SH, Pereira DI, Cavalheiro AS, Spanamberg A, Ferreiro L (2008) In vitro activities of voriconazole, itraconazole, and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil. Antimicrob Agents Chemother 52:767–769
pubmed: 18056274
doi: 10.1128/AAC.01075-07
Brito-Santos F, Reis RS, Coelho RA, Almeida-Paes R, Pereira SA, Trilles L, Meyer W, Wanke B, dos Santos LM, Gremião IDF (2019) Cryptococcosis due to Cryptococcus gattii VGII in southeast Brazil: The One Health approach revealing a possible role for domestic cats. Med Mycol Case Rep 24:61–64
pubmed: 31061785
pmcid: 6487353
doi: 10.1016/j.mmcr.2019.04.004
Chen M, Wang Y, Li Y, Hong N, Zhu X, Pan W, Liao W, Xu J, Du J, Chen J (2021) Genotypic diversity and antifungal susceptibility of environmental isolates of Cryptococcus neoformans from the Yangtze River Delta region of East China. Med Mycol 59:653–663
pubmed: 33269400
doi: 10.1093/mmy/myaa096
Chen Y-H, Yu F, Bian Z-Y, Hong J-M, Zhang N, Zhong Q-S, Hang Y-P, Xu J, Hu L-H (2018) Multilocus sequence typing reveals both shared and unique genotypes of Cryptococcus neoformans in Jiangxi Province, China. Sci Rep 8:1–12
Chong HS, Dagg R, Malik R, Chen S, Carter D (2010) In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 48:4115–4120
pubmed: 20844209
pmcid: 3020851
doi: 10.1128/JCM.01271-10
Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J (2011) In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 60:961–967
pubmed: 21393452
doi: 10.1099/jmm.0.029025-0
Clinical and Laboratory Standards Institute (CLSI) (2022) Epidemiological cutoff values for antifungal susceptibility testing. 4th ed. CLSI supplement M57S. Wayne, PA, USA. ISBN 978–1–68440–158–1 [Print]; 978–1–68440–159–8 [Electronic].
Dalhoff A, Ambrose PG, Mouton JW (2009) A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 37:296–305
pubmed: 19629383
doi: 10.1007/s15010-009-7108-9
Danesi P, Falcaro C, Schmertmann LJ, de Miranda LHM, Krockenberger M, Malik R (2021) Cryptococcus in wildlife and free-living mammals. J Fungi 7:29
doi: 10.3390/jof7010029
Dou H, Wang H, Xie S, Chen X, Xu Z, Xu Y (2017) Molecular characterization of Cryptococcus neoformans isolated from the environment in Beijing, China. Med Mycol 55:737–747
doi: 10.1093/mmy/myx026
Elhariri M, Hamza D, Elhelw R, Refai M (2015) Lovebirds and cockatiels risk reservoir of Cryptococcus neoformans, a potential hazard to human health. J Vet Sci Med Diagn 4(4):2
Ellabib MS, Aboshkiwa MA, Husien WM, D’Amicis R, Cogliati M (2016) Isolation, identification and molecular typing of Cryptococcus neoformans from pigeon droppings and other environmental sources in Tripoli, Libya. Mycopathologia 181:603–608
pubmed: 26943725
doi: 10.1007/s11046-016-9996-4
Ergin Ç, Şengül M, Aksoy L, Döğen A, Sun S, Averette AF, Cuomo CA, Seyedmousavi S, Heitman J, Ilkit M (2019) Cryptococcus neoformans recovered from olive trees (Olea europaea) in Turkey reveal allopatry with African and South American lineages. Front Cell Infect Microbiol 9:384
pubmed: 31788454
pmcid: 6856141
doi: 10.3389/fcimb.2019.00384
Espinel-Ingroff A, Aller A, Canton E, Castañón-Olivares L, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N (2012a) Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56:5898–5906
pubmed: 22948877
pmcid: 3486550
doi: 10.1128/AAC.01115-12
Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M et al (2012b) Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother 56:3107–3113
pubmed: 22391546
pmcid: 3370763
doi: 10.1128/AAC.06252-11
Fan X, Xiao M, Chen S, Kong F, Dou H-T, Wang H, Xiao Y-L, Kang M, Sun Z-Y, Hu Z-D, (2016) Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China. Clin Microbiol Infect 22;887:e881–887. e889.
Fang W, Fa Z, Liao W (2015) Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genet Biol 78:7–15
pubmed: 25445309
doi: 10.1016/j.fgb.2014.10.017
Firacative C, Meyer W, Castañeda E (2021) Cryptococcus neoformans and Cryptococcus gattii species complexes in Latin America: a map of molecular types, genotypic diversity, and antifungal susceptibility as reported by the Latin American Cryptococcal Study Group. J Fungi 7:282
doi: 10.3390/jof7040282
Ghannoum A, Rice B (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–517
pubmed: 10515900
pmcid: 88922
doi: 10.1128/CMR.12.4.501
Granados D, Castañeda E (2005) Isolation and characterization of Cryptococcus neoformans varieties recovered from natural sources in Bogotá, Colombia, and study of ecological conditions in the area. Microb Ecol 49:282–290
pubmed: 15965721
doi: 10.1007/s00248-004-0236-y
Grizante Barião PH, Tonani L, Cocio TA, Martinez R, Nascimento É, von Zeska Kress MR (2020) Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil. Mycoses 63:1341–1351
pubmed: 32869413
doi: 10.1111/myc.13174
Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32:2847–2849
pubmed: 27207943
doi: 10.1093/bioinformatics/btw313
Guerra CR, Ishida K, Nucci M, Rozental S (2012) Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology. Mem Inst Oswaldo Cruz 107:582–590
pubmed: 22850947
doi: 10.1590/S0074-02762012000500003
Gugnani HC, Hagen F, Meis JF, Chakrabarti A (2020) Occurrence of Cryptococcus neoformans and other yeast-like fungi in environmental sources in Bonaire (Dutch Caribbean). Germs 10:195
pubmed: 33134197
pmcid: 7572204
doi: 10.18683/germs.2020.1205
Gullo F, Rossi S, Sardi JdC, Teodoro V, Mendes-Giannini MJS, Fusco-Almeida A (2013) Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis 32:1377–1391
pubmed: 24141976
doi: 10.1007/s10096-013-1915-8
Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A (2015) Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India. Braz J Microbiol 46:1125–1133
pubmed: 26691471
pmcid: 4704646
doi: 10.1590/S1517-838246420140564
Hagen F, Illnait-Zaragozi M-T, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF (2010) In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54:5139–5145
pubmed: 20855729
pmcid: 2981230
doi: 10.1128/AAC.00746-10
Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, Falk R, Parnmen S, Lumbsch HT, Boekhout T (2015) Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 78:16–48
pubmed: 25721988
doi: 10.1016/j.fgb.2015.02.009
Hamilton-Miller J (1991) Calculating MIC50. J Antimicrob Chemother 27:863–864
pubmed: 1938695
doi: 10.1093/jac/27.6.863
Harris J, Lockhart S, Chiller T (2012) Cryptococcus gattii: where do we go from here? Sabouraudia 50:113–129
doi: 10.3109/13693786.2011.607854
Iqbal N, De Bass EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR (2010) Correlation of genotype and in-vitro susceptibilities of Cryptococcus gattii strains from the Pacific North west of the United States. J Clin Microbiol 48:539–544
pubmed: 20007380
doi: 10.1128/JCM.01505-09
Kangogo M, Boga H, Wanyoike W, Bii C (2014) Isolation and characterisation of Cryptococcus neoformans and Cryptococcus gattii from environmental sources in Nairobi, Kenya. East Afr Med J 91:281–285
pubmed: 26862653
Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R (2007) Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 60:312–316
pubmed: 17553813
doi: 10.1093/jac/dkm192
Kidd SE, Chow Y, Mak S, Bach PJ, Chen H, Hingston AO, Kronstad JW, Bartlett KH (2007) Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol 73:1433–1443
pubmed: 17194837
doi: 10.1128/AEM.01330-06
Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M et al (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A. 101:17258–17263
pubmed: 15572442
pmcid: 535360
doi: 10.1073/pnas.0402981101
Krangvichain P, Niyomtham W, Prapasarakul N (2016) Occurrence and susceptibilities to disinfectants of Cryptococcus neoformans in fecal droppings from pigeons in Bangkok, Thailand. J Vet Med Sci 78:391–396
pubmed: 26596636
doi: 10.1292/jvms.15-0594
Kwon-Chung KJ, Fraser JA, Doering TL, Wang ZA, Janbon G, Idnurm A, Bahn Y-S (2014) Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 4:a019760
pubmed: 24985132
pmcid: 4066639
doi: 10.1101/cshperspect.a019760
Li L, Wang J, Zhang Q, Wang J (2000) Isolation and identification of Cryptococcus neoformans from pigeon dropping. J Clin Dermatol 29:198–200
Leal LA, Faganello J, Cristina Bassanesi M, Vainstein MH (2008) Cryptococcus species identification by multiplex PCR. Med Mycol 46:377–383
pubmed: 18415847
doi: 10.1080/13693780701824429
May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K (2016) Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol 14:106–117
pubmed: 26685750
doi: 10.1038/nrmicro.2015.6
Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47:561–570
pubmed: 19462334
doi: 10.1080/13693780902953886
Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, Group ICS (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9:189
pubmed: 12603989
pmcid: 2901947
doi: 10.3201/eid0902.020246
Nweze EI, Kechia FA, Dibua UE, Eze C, Onoja US (2015) Isolation of Cryptococcus neoformans from environmental samples collected in Southeastern Nigeria. Rev Inst Med Trop Sao Paulo 57:295–298
pubmed: 26422152
pmcid: 4616913
doi: 10.1590/S0036-46652015000400004
Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1
pubmed: 12805255
doi: 10.1093/jac/dkg301
Olsen GL, Deitz KL, Flaherty HA, Lockhart SR, Hurst SF, Haynes JS (2012) Use of terbinafine in the treatment protocol of intestinal Cryptococcus neoformans in a dog. J Am Anim Hosp Assoc 48:216–220
pubmed: 22474053
doi: 10.5326/JAAHA-MS-5813
Park SH, Choi SC, Lee KW, Kim M-N, Hwang SM (2015) Genotypes of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Korea. Mycobiology 43:360–365
pubmed: 26539057
pmcid: 4630447
doi: 10.5941/MYCO.2015.43.3.360
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen M-H (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291–322
pubmed: 20047480
doi: 10.1086/649858
Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN (2011) Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 69:45–50
pubmed: 21146713
doi: 10.1016/j.diagmicrobio.2010.08.013
Pini G, Faggi E, Bravetti E (2017) Molecular typing of clinical and environmental Cryptococcus neoformans strains isolated in Italy. Open J Med Microbiol 7:77
doi: 10.4236/ojmm.2017.74007
Pllana-Hajdari D, Cogliati M, Čičmak L, Pleško S, Mlinarić-Missoni E, Mareković I (2019) First isolation, antifungal susceptibility, and molecular characterization of Cryptococcus neoformans from the environment in Croatia. J Fungi 5:99
doi: 10.3390/jof5040099
Prakash A, Randhawa HS, Khan ZU, Ahmad S, Hagen F, Meis JF, Chowdhary A (2018) Environmental distribution of Cryptococcus species and some other yeast-like fungi in India. Mycoses 61:305–313
pubmed: 29280202
doi: 10.1111/myc.12741
Refai M, El-Hariri M, Alarousy R (2017) Cryptococcosis in animals and birds: a review. Eur J Acad Essays 4:202–223
Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ (2016) Evaluation of antifungal combination against Cryptococcus spp. Mycoses 59:585–593
pubmed: 27135278
doi: 10.1111/myc.12510
Revelle W (2011) An overview of the psych package. Dep Psychol Northwest Univ 3:1–25
Romeo O, Scordino F, Criseo G (2011) Environmental isolation of Cryptococcus gattii serotype B, VGI/MATα strains in southern Italy. Mycopathologia 171:423–430
pubmed: 21253853
doi: 10.1007/s11046-010-9389-z
Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS (2012) Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains. Diagn Microbiol Infect Dis 72:332–339
pubmed: 22341512
doi: 10.1016/j.diagmicrobio.2011.11.016
Singh A, Panting RJ, Varma A, Saijo T, Waldron KJ, Jong A, Ngamskulrungroj P, Chang YC, Rutherford JC, Kwon-Chung KJ (2013) Factors required for activation of urease as a virulence determinant in Cryptococcus neoformans. Mbio 4:e00220-e213
pubmed: 23653445
pmcid: 3663189
doi: 10.1128/mBio.00220-13
Sirag B, Khidir E-S, Dumyati M, Sindi B, Alsinnari M, Faidah H, Ahmed A (2021) Cryptococcus neoformans and other opportunistic Cryptococcus species in pigeon dropping in Saudi Arabia: identification and characterization by DNA sequencing. FrontMicrobiol. 12:726203
Sorensen KN, Sobel RA, Clemons KV, Calderon L, Howell KJ, Irani PR, Pappagianis D, Williams PL, Stevens DA (2000) Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob Agents Chemother 44:3087–3091
pubmed: 11036027
pmcid: 101607
doi: 10.1128/AAC.44.11.3087-3091.2000
Taha M, Tartor Y, Ibrahim S, Abd El-Aziz R (2020) Molecular typing and susceptibility profile of Cryptococcus neoformans and Cryptococcus gattii species complex: An updated review. J Anim Health Prod 9:17–26
doi: 10.17582/journal.jahp/2020/9.s1.17.26
Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M (2012) Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 50:328–332
pubmed: 21859388
doi: 10.3109/13693786.2011.602126
Velagapudi R, Hsueh Y-P, Geunes-Boyer S, Wright JR, Heitman J (2009) Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 77:4345–4355
pubmed: 19620339
pmcid: 2747963
doi: 10.1128/IAI.00542-09
Walsh NM, Botts MR, McDermott AJ, Ortiz SC, Wüthrich M, Klein B, Hull CM (2019) Infectious particle identity determines dissemination and disease outcome for the inhaled human fungal pathogen Cryptococcus. PLoS Pathog 15:e1007777
pubmed: 31247052
pmcid: 6597114
doi: 10.1371/journal.ppat.1007777
Wei T, Simko V, Levy M, Xie Y, Jin Y, Zemla J (2017) Package ‘corrplot.’ Statistician 56:e24
Yu J, Li R, Zhang M, Liu L, Wan Z (2008) In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med Mycol 46:745–747
pubmed: 18608889
doi: 10.1080/13693780802163438
Zhang S, Li R, Yu J (2013) Drug combinations against Mucor irregularis in vitro. Antimicrob Agents Chemother 57:3395–3397
pubmed: 23587956
pmcid: 3697376
doi: 10.1128/AAC.02612-12